Abstract
Data from longitudinal paediatric Duchenne Muscular Dystrophy (DMD) cohorts has shown significant benefits of corticosteroids (CS) in patient treatment and management. Additionally, current scientific literature suggests that CS therapy delays the onset of pulmonary decline by approximately two years. However, there is limited data on the effects of CS in patients after loss of ambulation. Despite the updated in 2018 standards of care for DMD, there is still inconsistency in clinical care for non-ambulant patients across the UK.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
